Showing 3781-3790 of 7543 results for "".
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Cerave Poll: Healthier Skin Tops New Year’s Resolutionshttps://practicaldermatology.com/news/cerave-poll-healthier-skin-tops-new-years-resolution-lists/2460652/The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51
- DermTech Closes Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shareshttps://practicaldermatology.com/news/dermtech-closes-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/2460651/DermTech, Inc. closed its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share, the company
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there ar
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Metabolic Syndrome Linked to Higher Cardiovascular Risk in Psoriasis Patientshttps://practicaldermatology.com/news/metabolic-syndrome-linked-to-higher-cardiovascular-risk-in-psoriasis-patients/2460645/Metabolic syndrome in people with psoriasis may contribute to an increased risk of heart disease, according to a study in the Journal of the American Association of Dermatology. &ldqu
- Gene Sequencing May Quantify Risk of Skin Cancer Long Before Damage is Visiblehttps://practicaldermatology.com/news/gene-sequencing-may-quantify-risk-of-skin-cancer-long-before-damage-is-visible/2460644/New research sheds light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. In a study published&nbs
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom